Evox Therapeutics

Oxford, UK
Hybrid — also manufactures internal programs
Exosome
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-02
57.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (2) ○ EMA GMP ○ MHRA GMP

Quick Facts: Evox Therapeutics

Signal Score
57.5/100 (as of 2026-04-02)
Quality Compliance
Assessment pending
Headquarters
Oxford, UK
Modalities
Exosome
Active Programs
No ClinicalTrials.gov matches confirmed — 2 partnership announcements in press
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 2 partnership announcements found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesExosome
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 55.0
1 manufacturing site: Oxford, UK
Modalities: Exosome
Capacity assessment: 55.0/100
Sites: Oxford, UK
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press2 articles
1 manufacturing site: Oxford, UK
Modalities: Exosome
Capacity assessment: 55.0/100

Recent News 2 articles

partnership 2026-02-26
Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit® Technology to Enable Gene Editing in Rett Syndrome - BioSpace
Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit® Technology to Enable Gene Editing in Rett Syndrome  BioSpace
Source →
partnership 2026-02-26
Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit - Business Wire
Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit  Business Wire
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Exosome CDMOs →

Similar CDMOs

Codiak BioSciences (Sarepta)
Cambridge, MA
Signal Score: 78.0
Exosome
Esco Aster
Singapore, SG
Signal Score: 63.0
Cell Therapy, Exosome
ExoXpert (EXO Biologics)
Liege, BE
Signal Score: 56.5
Exosome
Exopharm
Melbourne, AU
Signal Score: 56.5
Exosome
Clara Biotech
Indianapolis, IN
Signal Score: 56.5
Exosome